Tamir Biotechnology, Inc. (formerly Alfacell Corporation) is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE®, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of therapies for cancer, viral, and other life-threatening diseases. Currently, Tamir is conducting a Phase II clinical trial with the addition of RANPIRNASE (ONCONASE®) to PEMETREXED plus CARBOPLATIN in patients with non-squamous, non-small cell lung cancer (NSCLC).

ONCONASE® is a first-in-class therapeutic based on Tamir's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE® has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE® triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

Tamir's proprietary drug discovery program is also the basis for the development of recombinant designed RNases for chemical conjugation and fusion (gene and protein) products with various targeting moieties, such as monoclonal antibodies, growth factors, and cytokines. This program also provides for joint design and development of new products with outside partners seeking line-extensions and/or improvements of the therapeutic effectiveness of their existing products. The reproducibility of our conjugation and fusion methodologies and the stability of these products has been demonstrated, and thus can be produced in a cost-effective and controlled manufacturing environment.



November 29, 2010
New Discovery May Offer Cure for Human Papillomavirus (HPV)

September 28, 2010
New Discovery Targets Cytomegalovirus (CMV)

August 10, 2010
New Hope in Finding Cure for Yellow Fever

July 21, 2010
Tamir Reports Positive Effect Against SARS Virus

July 19, 2010
Tamir's Compounds Show Remarkable Results Against Dengue Virus

July 16, 2010
Tommy G. Thompson, Former Secretary of Health and Human Services, Appointed to Tamir Biotechnology, Inc. as Special Advisor to CEO and Chairman of Oncology and Anti-Viral Business Development Advisory Committee

July 6th, 2010
Tamir Biotechnology, Inc. Announces Selection of CRO

May 3, 2010
Tamir Biotechnology Filed Resale Registration Statement as Required by the Investor Rights Agreement in a Previously Closed Private Placement

March 26th, 2010
Alfacell Provides Annual Report

March 26th, 2010
Alfacell announces Annual Meeting

October 20, 2010
Alfacell Corporation Announces Closing of $3.25 Million Private Placement

June 19th, 2009
Alfacell Provides Shareholder Update

January 27th, 2009
Alfacell Provides ONCONASE® NDA Submission Update

January 5th, 2009
Alfacell Announces Receipt of NASDAQ Panel Decision




Press Release Archive
All Archived Press Releases are now easily available for viewing




Alfacell Slide Presentation for Annual Shareholders Meeting April 27, 2010

Honorable Tommy Thompson (Former Secretary of Health and Human Services)
Video Message to Shareholders April 27, 2010

Dr. Darzynkiewicz (NY Medical College) Video Message to Shareholders April 27, 2010

Dr. Harvey Pass (NYU Medical Center) Video Message to Shareholders April 27, 2010

Waging War on Cancer 202: Mesothelioma: The Hidden Threat

Effect of Onconase on Double-Stranded RNA In Vitro

Local Controlled Delivery of Anti-Neoplastic RNAse to the Brain

Ranprinase as a potential antitumor ribonuclease treatment for mesothelioma
and other malignancies

Learn more about the ONCONASE® mechanism in action!

Audit Committee Charter

Compensation Committee Charter

Corporate Governance and Nominating Committee Charter